Alios has an RSV drug (AL-8176) in phase-2 and an HCV nuke in preclinical development, as noted in #msg-106165891. JNJ’s PR doesn’t mention the HCV nuke, but it's reasonable to surmise that the HCV nuke influenced the deal value to a non-trivial degree.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”